Related Experiment Video

Updated: Jun 6, 2026

A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors
09:04

A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors

Published on: March 15, 2016

Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: mechanisms and potential use

Emily S Robinson1, Eliyahu V Khankin, S Ananth Karumanchi

  • 1Brigham and Women's Hospital, Boston, Massachusetts, USA.

Seminars in Nephrology
|December 15, 2010
PubMed

Insights

Vascular endothelial growth factor (VEGF) targeted therapies for cancer can cause hypertension as an on-target side effect. This review explores mechanisms, clinical implications, and the potential of blood pressure increase as a biomarker for effective treatment.

Area of Science:

  • Oncology
  • Pharmacology
  • Cardiovascular Medicine

Background:

  • Vascular endothelial growth factor (VEGF) signaling pathway inhibitors are a growing class of targeted cancer therapies.
  • These therapies offer improved specificity and reduced side effects compared to traditional chemotherapy.
  • A significant side effect is hypertension, occurring in 30-80% of patients.

Purpose of the Study:

  • To review the mechanisms underlying VEGF-targeted therapy-induced hypertension.
  • To discuss the parallels between this hypertension and preeclampsia.
  • To explore therapeutic implications and the potential of hypertension as a biomarker.

Main Methods:

  • Literature review of current understanding of VEGF-targeted therapy-induced hypertension.
  • Comparative analysis of VEGF-targeted therapy-induced hypertension and preeclampsia.
  • Discussion of clinical management strategies and biomarker potential.

Main Results:

  • Hypertension is an on-target toxicity, reflecting effective VEGF pathway inhibition.
  • Similarities exist between VEGF-targeted therapy-induced hypertension and preeclampsia mechanisms.
  • Elevated blood pressure may serve as a biomarker for drug efficacy.

Conclusions:

  • Understanding the mechanisms of VEGF-targeted therapy-induced hypertension is crucial for clinical management.
  • Further research into the similarities with preeclampsia may yield therapeutic insights.
  • Monitoring blood pressure can guide dosing and confirm effective VEGF pathway inhibition.

More Related Videos

Demonstrating a Linear Relationship Between Vascular Endothelial Growth Factor and Luteinizing Hormone in Kidney Cortex Extracts05:56

Demonstrating a Linear Relationship Between Vascular Endothelial Growth Factor and Luteinizing Hormone in Kidney Cortex Extracts

Published on: January 22, 2020

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...